Genetics: Personalized medicine and tumour heterogeneity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. On-chip modeling of tumor evolution: Advances, challenges and opportunities.Materials today. Bio · 2023
   Review
2. The case for AI-driven cancer clinical trials - The efficacy arm in silico.Biochimica et biophysica acta. Reviews on cancer · 2021
   Review
3. A novel workflow for cancer blood biomarker identification.Annals of translational medicine · 2020
   Article
4. Culture and application of conditionally reprogrammed primary tumor cells.Gastroenterology report · 2020
   Review
5. A Bayesian hidden Potts mixture model for analyzing lung cancer pathology images.Biostatistics (Oxford, England) · 2019
   Article
6. Loperamide, an antidiarrheal agent, induces apoptosis and DNA damage in leukemia cells.Oncology letters · 2018
   Article
7. Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer PatientsAsian Pacific journal of cancer prevention : APJCP · 2017
   Article
8. Managing Expectations in the Transition to Proof of Concept Studies.Reviews on recent clinical trials · 2017
   Review
9. Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.British journal of clinical pharmacology · 2016
   Review
10. Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories.Clinical and translational medicine · 2014
    Article
11. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes.Theranostics · 2014
    Article
12. Technologies for deriving primary tumor cells for use in personalized cancer therapy.Trends in biotechnology · 2013
    Review
13. Building a personalized medicine infrastructure at a major cancer center.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Review

Corrections and comments

• Comment on
  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.